Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Clin Infect Dis. 2018 Jul 2;67(2):179-185. doi: 10.1093/cid/ciy075.
To provide a standardized, risk-adjusted method for summarizing antibiotic use (AU), enable hospitals to track their AU over time and compare their AU data to national benchmarks, the Centers for Disease Control and Prevention developed the Standardized Antimicrobial Administration Ratio (SAAR).
Hospitals reporting to the National Healthcare Safety Network (NHSN) AU Option collect and submit aggregated AU data electronically as antimicrobial days of therapy per patient days present. SAARs were developed for specific NHSN adult and pediatric patient care locations and cover five antimicrobial agent categories: (1) broad-spectrum agents predominantly used for hospital-onset/multi-drug resistant bacteria; (2) broad-spectrum agents predominantly used for community-acquired infections; (3) anti-methicillin-resistant Staphylococcus aureus agents; (4) agents predominantly used for surgical site infection prophylaxis; and (5) all antibiotic agents. The SAAR is an observed-to-predicted use ratio where predicted use is estimated from a statistical model; a SAAR of 1 indicates that observed use and predicted use are equal.
Most location-level SAARs were statistically significantly different than 1: adult locations up to 52% lower than 1 and up to 41% higher than 1. Median SAARs in adult and pediatric ICUs had a range of 0.667-1.119. SAAR distributions serve as an external comparison to national SAARs.
This is the first aggregate AU metric that uses point-of-care, antimicrobial administration data electronically reported to a national surveillance system to enable risk-adjusted, AU comparisons across multiple hospitals. Endorsed by the National Quality Forum, SAARs provide AU benchmarks that stewardship programs can use to help drive improvements.
为了提供一种标准化、风险调整的方法来总结抗生素的使用情况,使医院能够跟踪其抗生素的使用情况随时间的变化,并将其抗生素使用数据与国家基准进行比较,疾病预防控制中心制定了标准化抗菌药物管理比(SAAR)。
向国家医疗保健安全网络(NHSN)抗生素使用选项报告的医院通过电子方式收集和提交汇总的抗生素使用数据,每患者住院日的抗生素治疗日数。SAAR 是针对 NHSN 成人和儿科患者护理地点开发的,涵盖五类抗菌药物类别:(1)主要用于医院获得性/多药耐药菌的广谱药物;(2)主要用于社区获得性感染的广谱药物;(3)抗耐甲氧西林金黄色葡萄球菌药物;(4)主要用于手术部位感染预防的药物;和(5)所有抗生素药物。SAAR 是观察到的与预测使用的比率,其中预测使用是从统计模型中估计的;SAAR 为 1 表示观察到的使用和预测的使用相等。
大多数地点级别的 SAAR 明显低于 1:成人地点低至 52%,高至 41%。成人和儿科 ICU 的中位数 SAAR 范围为 0.667-1.119。SAAR 分布可作为与国家 SAAR 的外部比较。
这是第一个使用电子方式从国家监测系统报告的床边抗菌药物管理数据来进行风险调整的抗生素使用综合指标,以实现多家医院之间的抗生素使用比较。SAAR 得到了国家质量论坛的认可,为管理计划提供了抗生素使用基准,以帮助推动改进。